Format

Send to

Choose Destination
J Clin Neuromuscul Dis. 2016 Sep;18(1):21-7. doi: 10.1097/CND.0000000000000131.

Comparative Long-Term Evaluation of Patients With Juvenile Inflammatory Myopathies.

Author information

1
*UTHSC, Memphis, TN; ‡Le Bonheur Medical Center, Memphis, TN; and §UAB, Birmingham, AL.

Abstract

OBJECTIVES:

We conducted a retrospective study analyzing the clinical features, laboratory findings, demographics, and long-term prognoses of patients with juvenile inflammatory myopathies to determine possible predictors indicating the use of aggressive immunotherapy and the response to and complications of treatment.

METHODS:

The medical records of 41 patients with juvenile inflammatory myopathies seen at University of Tennessee-affiliated hospitals in Memphis from 1969 to 2008 were evaluated. Patients' clinical characteristics, laboratory studies, muscle biopsies, and electromyography were reviewed. All patients were treated with prednisone initially; additionally, 14 patients received varying combinations of other immunosuppressant therapies.

RESULTS:

Seventy-three percent of the patients experienced remission. Patients in the group that did not go into remission had specific characteristics at onset: they were comparatively older and had more severe rashes, contractures, arthritis, and systemic involvement. Also, patients with positive autoantibodies (antinuclear antibody, rheumatoid arthritis factor) had better outcomes.

CONCLUSIONS:

Juvenile inflammatory myopathies have relatively good prognoses. Initial presentation at advanced age or with severe rash, systemic vasculopathies, anemia, or arthritis portends refractory disease; in these patients, second- and third-line therapies improve outcome.

PMID:
27552385
DOI:
10.1097/CND.0000000000000131
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center